Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy

CURRENT-OASIS 7 Steering Committee, Shamir R Mehta, Jean-Pierre Bassand, Susan Chrolavicius, Rafael Diaz, Keith A A Fox, Christopher B Granger, Sanjit Jolly, Hans-Jurgen Rupprecht, Petr Widimsky, Salim Yusuf

Research output: Contribution to journalArticlepeer-review

Abstract

Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS). Recent mechanistic and clinical data suggest that higher loading and maintenance doses of clopidogrel may achieve a more rapid and greater degree of platelet inhibition that translates into improved clinical outcomes, but this is yet to be formally evaluated in an adequately powered randomized trial.
Original languageEnglish
Pages (from-to)1080-1088
Number of pages9
JournalAmerican Heart Journal
Volume156
Issue number6
DOIs
Publication statusPublished - Dec 2008

Fingerprint Dive into the research topics of 'Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy'. Together they form a unique fingerprint.

Cite this